Brain zaps for depression? DBS device tested in 46 patients

NCT ID NCT03653858

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether deep brain stimulation (DBS) can help people with severe depression that hasn't responded to other treatments. 46 patients received either active DBS or a sham (inactive) device. The goal was to see if DBS reduces depression symptoms safely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
deep brain stimulation (DBS) device
What this could lead to
If it works, this could offer a new option for people with severe depression that hasn't improved with other treatments.
What could go wrong
This is a small, early-stage trial with only 46 participants. The effects may not be large or lasting, and brain surgery carries risks like infection or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

46 people

The number who actually took part.

Started

Sep 2018

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Major depression (MD), severe, unipolar, or bipolar in an acute depression episode. 2. German mother tongue or fluent. 3. Male or female patients ≥20 and ≤75 years. 4. Hamilton Depression Rating Scale (HDRS-28) score of \>21. 5. Global Assessment of Function (GAF) score of \<45. 6. At least 4 episodes of depression or one chronic episode \>2 years. 7. Failure to respond to 1. adequate trials of primary antidepressants from at least 3 different classes (\>5 weeks at the maximum recommended or tolerated dose) and 2. adequate trials of augmentation/combination of a primary antidepressant (\>3 weeks at the usually recommended or maximum tolerated dose) using at least 2 different augmenting/combination agents (lithium, T3, stimulants, neuroleptics, anticonvulsants, buspirone, or a second primary antidepressant) and 3. an adequate trial of electroconvulsive therapy (ECT) (\>6 treatments) and an adequate trial of individual psychotherapy (\>20 sessions with an experienced psychotherapist). 8. Able to give written informed consent. 9. Compliance to participate in the study. 10. Drug free or on stable drug regimen at least 6 weeks before study entry. Exclusion Criteria: 1. Current or past non-affective psychotic disorder. 2. Any current clinically significant neurological disorder or medical illness affecting brain function, other than motor tics or Gilles de la Tourette syndrome. 3. Any clinically significant abnormality on preoperative magnetic resonance imaging (MRI), any contraindications to perform a planned MRI to visualize the slMFB. 4. Any surgical contraindications to undergoing DBS like deformed or displaced or not discernable target region, scarring after brain disease (infarction), need for continuous anticoagulation that cannot be bridged in order to obtain normal coagulation, present risks for anesthesia or any brain or scalp injury (even after intracranial surgery). 5. Current or unstably remitted substance abuse (aside from nicotine). 6. Pregnancy, women of childbearing age not using effective contraception and breast feeding women. 7. History of severe personality disorder. 8. Acute suicidal ideation. 9. Patients with advanced stage cardiovascular disease. 10. Patients under immunosuppressive or chemo therapy because of malignant disease. 11. Patients who had previous intracranial surgery. 12. Patients who are currently under DBS therapy or have implanted any kind of stimulator already. 13. Patients with aneurysm clips. 14. Patients with cochlear implants. 15. Patients with planned diathermy. 16. Persons who are in a relationship of dependence/employment with the sponsor or the investigator. 17. Simultaneous participation or previous participation within 30 days prior to start of screening in a clinical trial involving investigational medicinal product(s) or investigational medical device(s).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Treatment resistant depression are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital Freiburg

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Université Grenoble Alpes

    Grenoble, 38043, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.